143 related articles for article (PubMed ID: 20202054)
41. Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation.
Boehm A; Sperr WR; Leitner G; Worel N; Oehler L; Jaeger E; Mitterbauer M; Haas OA; Valent P; Kalhs P; Rabitsch W
Eur J Clin Invest; 2008 Dec; 38(12):945-52. PubMed ID: 19021720
[TBL] [Abstract][Full Text] [Related]
42. Clinical, hematological and histomorphological profile of myelodysplastic syndrome.
Nigam S; Rani S; Singh T; Gupta S; Rakheja D; Gaiha M
J Assoc Physicians India; 2001 Apr; 49():430-4. PubMed ID: 11762613
[TBL] [Abstract][Full Text] [Related]
43. [A man with a painful abnormality on his lower leg].
Tenhagen M; Lindauer-van der Werf G; Cense HA
Ned Tijdschr Geneeskd; 2012; 156(50):A4926. PubMed ID: 23231870
[TBL] [Abstract][Full Text] [Related]
44. Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia.
Follo MY; Finelli C; Clissa C; Mongiorgi S; Bosi C; Martinelli G; Baccarani M; Manzoli L; Martelli AM; Cocco L
J Clin Oncol; 2009 Feb; 27(5):782-90. PubMed ID: 19114693
[TBL] [Abstract][Full Text] [Related]
45. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
[TBL] [Abstract][Full Text] [Related]
46. [Langerhans histiocytosis and acute monoblastic leukemia type LMA4].
Hermanns-Lê T; Arrese JE; Piérard GE
Ann Dermatol Venereol; 1998 Feb; 125(2):124-6. PubMed ID: 9747230
[TBL] [Abstract][Full Text] [Related]
47. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia.
Blau O; Hofmann WK; Baldus CD; Thiel G; Serbent V; Schümann E; Thiel E; Blau IW
Exp Hematol; 2007 Feb; 35(2):221-9. PubMed ID: 17258071
[TBL] [Abstract][Full Text] [Related]
48. Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance.
Georgiou G; Karali V; Zouvelou C; Kyriakou E; Dimou M; Chrisochoou S; Greka P; Dufexis D; Vervesou E; Dimitriadou E; Efthymiou A; Petrikkos L; Dima K; Lilakos K; Panayiotidis P
Br J Haematol; 2006 Aug; 134(3):302-6. PubMed ID: 16787503
[TBL] [Abstract][Full Text] [Related]
49. ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome.
Wang H; Wang XQ; Xu XP; Lin GW
Leuk Res; 2010 May; 34(5):598-604. PubMed ID: 19853913
[TBL] [Abstract][Full Text] [Related]
50. Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients.
Maschek H; Georgii A; Kaloutsi V; Werner M; Bandecar K; Kressel MG; Choritz H; Freund M; Hufnagl D
Eur J Haematol; 1992 Apr; 48(4):208-14. PubMed ID: 1592101
[TBL] [Abstract][Full Text] [Related]
51. Identification of a metabolic gene panel to predict the prognosis of myelodysplastic syndrome.
Hu F; Chen SL; Dai YJ; Wang Y; Qin ZY; Li H; Shu LL; Li JY; Huang HY; Liang Y
J Cell Mol Med; 2020 Jun; 24(11):6373-6384. PubMed ID: 32337851
[TBL] [Abstract][Full Text] [Related]
52. Cancer in myelodysplastic syndromes.
Nakayama S; Ishikawa T; Yabe H; Nagai K; Kasakura S
Nihon Ketsueki Gakkai Zasshi; 1990 Feb; 53(1):84-8. PubMed ID: 2330809
[TBL] [Abstract][Full Text] [Related]
53. Atypical features of primary myelodysplastic syndrome.
Pati H; Bhargava M; Kochupillai V
Indian J Med Res; 1986 Nov; 84():516-8. PubMed ID: 3470255
[No Abstract] [Full Text] [Related]
54. Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study.
de Hollanda A; Beucher A; Henrion D; Ghali A; Lavigne C; Lévesque H; Hamidou M; Subra JF; Ifrah N; Belizna C
Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1188-94. PubMed ID: 21584947
[TBL] [Abstract][Full Text] [Related]
55. Regulatory T cells and progenitor B cells are independent prognostic predictors in lower risk myelodysplastic syndromes.
Kahn JD; Chamuleau ME; Westers TM; Van de Ven PM; van Dreunen L; van Spronsen M; Ossenkoppele GJ; van de Loosdrecht AA
Haematologica; 2015 Jun; 100(6):e220-2. PubMed ID: 25749828
[No Abstract] [Full Text] [Related]
56. Disseminated cutaneous granulomatous eruptions associated with myelodysplastic syndrome and acute myeloid leukaemia.
Vestey JP; Turner M; Biddlestone L; McLaren K; Goulden N; Hunter JA
Clin Exp Dermatol; 1993 Nov; 18(6):559-63. PubMed ID: 8252798
[TBL] [Abstract][Full Text] [Related]
57. Myelodysplastic syndrome presenting as cutaneous purpura.
Fein H; Adams BB
Cutis; 2000 Jun; 65(6):367-70. PubMed ID: 10879305
[TBL] [Abstract][Full Text] [Related]
58. Application of the revised International Prognostic Scoring System for myelodysplastic syndromes in Argentinean patients.
Belli CB; Bestach Y; Giunta M; Iastrebner M; Santos I; Pintos N; Arbelbide J; Basquiera AL; Bengió R; Larripa I
Ann Hematol; 2014 Apr; 93(4):705-7. PubMed ID: 23892924
[No Abstract] [Full Text] [Related]
59. Acquired reactive perforating collagenosis associated with myelodysplastic syndrome evolving to acute myelogenous leukaemia.
Karpouzis A; Tsatalas C; Sivridis E; Kotsianidis I; Margaritis D; Kouskoukis C; Bourikas G
Australas J Dermatol; 2004 Feb; 45(1):78-9. PubMed ID: 14961919
[No Abstract] [Full Text] [Related]
60. Acute myeloid leukemia and myelodysplastic syndrome-associated Sweet syndrome: A comparative multicenter retrospective study of 39 patients.
Merlant M; Lepelletier C; Battistella M; Vignon-Pennamen MD; Duriez P; Moguelet P; Brunet-Possenti F; Bagot M; Chasset F; Bouaziz JD
J Am Acad Dermatol; 2021 Mar; 84(3):838-840. PubMed ID: 33065169
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
